Oculis Holding AG (OCS) Research

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Market snapshot

Symbol
OCS
Price
$11.22
Day change
-0.71%
Market cap
$516.8M
P/E ratio
-5.60x
52-week range
10.52-34.475
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$39.40

Peer companies

  • AnaptysBio, Inc. (ANAB)
  • BridgeBio Oncology Therapeutics Inc. (BBOT)
  • Kodiak Sciences Inc. (KOD)
  • Mind Medicine (MindMed) Inc. (MNMD)
  • Nektar Therapeutics (NKTR)
  • Nurix Therapeutics, Inc. (NRIX)
  • Phathom Pharmaceuticals, Inc. (PHAT)
  • Sana Biotechnology, Inc. (SANA)

Open Oculis Holding AG (OCS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.